CG Oncology Reports Phase 3 Win for Bladder Cancer Immunotherapy, Plans Expanded FDA Discussions
By Dr. Zubair Khalid, DVM, MS, PhD ·

CG Oncology has reported positive results from a late-stage study of its immunotherapy cretostimogene in patients with non-muscle invasive bladder cancer (NMIBC). The treatment reduced the risk of tumor recurrence in certain patients following surgery. Based on the data, the company is now preparing new, expanded plans to discuss with the U.S. Food and Drug Administration.
The Phase 3 trial evaluated cretostimogene in a specific subset of NMIBC patients. The outcome broadens the clinical potential of the therapy, which is designed to stimulate the immune system to target cancer cells. CG Oncology intends to use the results to support a broader regulatory strategy.
Bladder cancer is one of the most common cancers worldwide. Non-muscle invasive forms account for about 75 percent of new cases and carry a high risk of recurrence after initial surgical treatment. Current standard-of-care options include intravesical therapies such as BCG, but many patients do not respond or eventually relapse. Immunotherapies like cretostimogene represent an alternative approach that may help delay or prevent recurrence while preserving the bladder. The positive Phase 3 data could lead to a new treatment option for patients who have limited choices after surgery.
Source: original report